Evidence mapPaperPMID 41484072Full record

ArticleLight, science & applications2026

Single-capillary endothelial dysfunction resolved by optoacoustic mesoscopy.

Hailong He, Angelos Karlas, Nikolina-Alexia Fasoula, Chiara Fischer, Ulf Darsow, Michael Kallmayer, Juan Aguirre, Hans-Henning Eckstein, Vasilis Ntziachristos

Abstract read
In one paragraph

Article in Light, science & applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hailong He *Chair of Biological Imaging, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health & School of Computation, Information and Technology, Technical University of Munich, Munich, Germany.
Angelos Karlas *Chair of Biological Imaging, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health & School of Computation, Information and Technology, Technical University of Munich, Munich, Germany.
Nikolina-Alexia FasoulaChair of Biological Imaging, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health & School of Computation, Information and Technology, Technical University of Munich, Munich, Germany.
Chiara FischerDepartment of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Ulf DarsowDepartment of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Michael KallmayerClinic and Polyclinic for Vascular and Endovascular Surgery, TUM University Hospital, Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
Juan AguirreChair of Biological Imaging, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health & School of Computation, Information and Technology, Technical University of Munich, Munich, Germany.
Hans-Henning EcksteinDZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
Vasilis NtziachristosChair of Biological Imaging, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health & School of Computation, Information and Technology, Technical University of Munich, Munich, Germany. bioimaging.translatum@tum.de.ORCID http://orcid.org/0000-0002-9988-0233

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) No 101017802 (OPTOMICS)EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) No 687866 (INNODERM)EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) No 694968 (PREMSOT)EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) No 862811 (RSENSE)EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) No 871763 (WINTHER)Helmholtz Association Initiative and Networking Fund i3 (ExNet-0022-Phase2-3)Helmholtz Association Initiative and Networking Fund, i3 (ExNet-0022-Phase2-3)Helmholtz Association Physician Scientists for Groundbreaking Projects
6 · The paper itself

Abstract

Microvascular endothelial dysfunction (MiVED) is an early marker of endothelial impairment, often preceding dysfunction in large arteries. Although MiVED assessment could reveal new insights into the pathophysiology of cardiovascular disease (CVD) or offer earlier detection and finer disease stratification, detailed in-vivo MiVED observation remains challenging due to a lack of suitable technologies. To address this gap, we hypothesized that accelerating ultra-wideband raster-scan optoacoustic mesoscopy (RSOM), i.e., fast RSOM (fRSOM), could resolve for the first time cutaneous MiVED features at single capillary resolution. We investigated whether we could record morphological features and dynamic responses during post-occlusive reactive hyperemia to achieve the most detailed observation of microvascular endothelial function to date. Our results show that using fRSOM on skin clearly measured the effects of smoking (N = 20) and atherosclerotic CVD (N = 20) on cutaneous endothelial function. For the first time, we found layer-specific effects, with smoking and CVD affecting the sub-papillary dermis differently than the reticular dermis; a finding not resolvable using "bulk" volumetric signals from laser Doppler flowmetry or tissue spectrometry. Interestingly, we observed no substantial structural changes in the microvasculature of smokers and volunteers with CVD, indicating that MiVED may be an earlier marker than morphology-based biomarkers typically assessed by histological studies. Our study introduces a non-invasive modality that enables the visualization and quantification of skin microvascular structure and function, bridging a technological gap and offering new insights into the effects of diseases on MiVED. This study potentially paves the way for fRSOM use as an early detection, diagnostic, or theranostic marker.

Identifiers

PMID41484072
PMCPMC12764958

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.